Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Celgene
Woman and Man Max 99 years
Celgene Corporation
Update Il y a 4 ans
Phase 3 study to evaluate safety and effectiveness of oral Apremilast (CC-10004) in patients with Psoriatic Arthritis
The primary objective of the study is to evaluate the clinical efficacy of 2 doses of apremilast (20 mg or 30 mg orally BID) compared with placebo, on the signs and symptoms of psoriatic arthritis (Ps...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Celgene Corporation
Update Il y a 4 ans
Phase 3 study to evaluate safety and effectiveness of oral Apremilast (CC-10004) in patients with Psoriatic Arthritis who have not been previously treated with disease-modifiying antirheumatic drugs
The primary objective of the study is to evaluate the clinical efficacy of 2 doses of apremilast (20 mg or 30 mg orally BID) compared with placebo, on the signs and symptoms of psoriatic arthritis (Ps...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Celgene Corporation
Update Il y a 4 ans
Investigation to Efficacy and Safety of CC-90001 in patients with Idiopathic Pulmonary Fibrosis
To evaluate the effect of CC-90001, 200 mg and 400 mg, when orally administered (PO) once daily (QD), compared with placebo, on percent of predicted forced vital capacity (FVC) after 24 weeks of tre...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Max and 99 years
Celgene
Update Il y a 4 ans
Étude GC-LTFU-001 : étude de phase 2-3 de suivi à long terme évaluant la sécurité et l’efficacité d’un traitement par cellules T génétiquement modifiées chez des patients ayant reçu un tel traitement.
Les lymphocytes T représentent les principaux acteurs de l’immunité antitumorale. Ils possèdent un récepteur, appelé TCR, qui leur permet de reconnaître certains éléments des cellules cancéreuses. Ces...
Country
France
organs
Tout Cancer
Specialty
Thérapie Cellulaire
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
Celgene Corporation
Update Il y a 4 ans
A study to evaluate the drug Mongersen (GED-0301) for the treatment of Crohn's disease in adults and adolescents
Evaluate efficacy of GED-0301 at Week 12, administered as either a single 160 mg tablet or as four 40 mg tablets, compared with placebo on clinical activity in subjects with active CD
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years
and 99 years
Celgene
Update Il y a 4 ans
Étude JCAR017-BCM-001 : étude de phase 2 évaluant l’efficacité et la tolérance du lisocabtagene maraleucel chez des patients adultes ayant un lymphome non hodgkinien à cellules B agressif.
Les hémopathies malignes regroupent un ensemble de cancers des cellules sanguines et de leurs précurseurs comme les leucémies et les lymphomes. Les cellules souches hématopoïétiques sont fabriquées pa...
Country
France
organs
Lymphomes non hodgkinien
Specialty
Chimiothérapie
,
Thérapies Ciblées
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
Celgene Corporation
Update Il y a 4 ans
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects with Active Psoriatic Arthritis
To evaluate the clinical efficacy of 2 doses of apremilast (20 mg or 30 mg orally twice per day [BID]), compared with placebo, on the signs and symptoms of psoriatic arthritis (PsA) after 24 weeks’ ad...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Celgene International II Sàrl
Update Il y a 4 ans
A study to assess the safety and clinical activity of durvalumab as combination therapy on previously untreated people with high risk diffuse large b-cell lymphoma
The primary objective of the study is to explore the clinical activity of durvalumab (MEDI4736) in combination with R-CHOP (non-activated B-cell) or R2-CHOP (activated B-cell) followed by durvalumab c...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years
and 99 years
Celgene
Update Il y a 4 ans
CC-5013-DLC-001 : Essai de phase 2-3 randomisé comparant l’efficacité et la tolérance du lénalidomide à un traitement au choix de l’investigateur, chez des patients ayant un lymphome diffus à grandes cellules B réfractaire ou en rechute. [essai clos aux inclusions]
L’objectif de cet essai est de comparer l’efficacité et la tolérance du lénalidomide (Revlimid®) à un traitement standard, chez des patients ayant un lymphome diffus à grandes cellules B réfractaire o...
Country
France
organs
Lymphomes non hodgkinien
Specialty
Chimiothérapie
,
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Celgene Corporation
Update Il y a 4 ans
A study to assess the safety, feasibility and clinical activity of JCAR015, a CAR-T cell therapy, in adults with B-cell acute lymphoblastic leukemia Un estudio que evalúa la seguridad, viabilidad y actividad clinica de JCAR015, una terapia celular de CAR-T, en adultos con leucemia linfoblástica aguda de células B
Cohorts 1 – 4: To evaluate the efficacy of JCAR015 as measured by overall remission rate (ORR) after the final JCAR015 infusion in subjects with morphologic evidence of disease, based on independent r...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
1
2
3
4
5
6
7
8
9
10
Next